MSD Korea launches 9-valent cervical cancer, Gardasil 9
MSD Korea(CEO Avi Ben-Shoshan) announced a launch of its cervical cancer vaccine Gardasil 9(9-valent human papillomavirus vaccine). Gardasil 9 acquired domestic commercialization approval from the Ministry of Food and Drug Safety(MFDS) last January.
Gardasil 9, a 9-valent HPV recombinant vaccine...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
